Market Cap 278.73M
Revenue (ttm) 266.27M
Net Income (ttm) -50.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -18.94%
Debt to Equity Ratio -5.07
Volume 618,600
Avg Vol 1,128,242
Day's Range N/A - N/A
Shares Out 64.82M
Stochastic %K 49%
Beta 1.11
Analysts Strong Sell
Price Target $15.60

Company Profile

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 949 284 4555
Address:
520 Newport Center Drive, Suite 1200, Newport Beach, United States
GrimTicker
GrimTicker Feb. 18 at 6:58 AM
$EOLS Evolus markets Jeuveau in aesthetics, gaining share in neuromodulator market but facing entrenched Botox competition and pricing pressure [citation:historical].
0 · Reply
kevinjewlurz
kevinjewlurz Feb. 13 at 3:27 PM
$EOLS @YugoSuperBeasT It seems like market still assumes cosmetic adoption curve when reimbursement language clearly anticipates therapeutic migration… right? specifically once CPT crosswalk guidance exits provisional status. We’re only 2 months away from complete protocol disengagement
0 · Reply
Bohrenn
Bohrenn Feb. 11 at 4:00 PM
$EOLS Sharedeals.de No Brainer Club with another rocket — strong buy below $10 USD
1 · Reply
KatherineBarnett501
KatherineBarnett501 Feb. 11 at 2:26 PM
$EOLS Evolus; aesthetics biotech (Jeuveau); gaining share in neuromodulator market; faces entrenched competition from AbbVie's Botox; pricing pressure is a margin headwind.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 6 at 6:25 PM
$EOLS Current Stock Price: $4.47 Contracts to trade: $5.0 EOLS Feb 20 2026 Call Entry: $0.23 Exit: $0.41 ROI: 80% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
chivo12
chivo12 Feb. 5 at 8:52 PM
$EOLS what an epic failure by executive management and the BOD. Trading at 1X revenue 7 years after commercial launch, and basically ignored by the investment community. Revenue guidance terrible. No path to positive GAAP earnings due to executive management hogs gorging themselves at the RSU and stock option trough ($20M impact annually!) and massive operating expenses that necessitate huge borrowing costs ($20M impact annually!). They talk about profitability in 2026 but they only mean non-GAAP. They won’t hit GAAP profitability until 2027…….9 years after their first product launch! Shameful! It is time for CEO to act like a grown up and slash operating expenses and give more realistic sales guidance ($350M - $360M in 2026) or else it is time to vote the BOD jokers out for not holding CEO accountable for this mess.
4 · Reply
Scamstock
Scamstock Feb. 5 at 8:02 PM
$EOLS did my second of up to 3 well spread out DCA first was 5.00 after today’s buy my average is now down to 4.76 one buy left I think this is due for a longer term reversal
0 · Reply
Bohrenn
Bohrenn Feb. 5 at 5:25 PM
$EOLS Mega NBC-Empfehlung zu $10,24; Stark Kaufen unter $10 - Sharedeals.de No Brainer Club Depot YTD bereits bei -22%;
1 · Reply
Longboardsoul
Longboardsoul Jan. 27 at 3:38 PM
$EOLS Why does David Moatazedi still have a job after this performance?
0 · Reply
lknite
lknite Jan. 26 at 7:32 PM
$EOLS ok, im in
0 · Reply
Latest News on EOLS
Evolus, Inc. (EOLS) Q3 2025 Earnings Call Transcript

Nov 8, 2025, 4:16 PM EST - 3 months ago

Evolus, Inc. (EOLS) Q3 2025 Earnings Call Transcript


Evolus Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:05 PM EST - 3 months ago

Evolus Reports Third Quarter 2025 Financial Results


Evolus to Participate in 2025 Stifel Healthcare Conference

Oct 28, 2025, 8:00 AM EDT - 4 months ago

Evolus to Participate in 2025 Stifel Healthcare Conference


Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 7:15 PM EDT - 7 months ago

Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript


Evolus - A Slightly Risky Buy Ahead Of Q2 Earnings

Jul 21, 2025, 5:20 PM EDT - 7 months ago

Evolus - A Slightly Risky Buy Ahead Of Q2 Earnings


Evolysse™ Recognized in 2025 Shape Skin Awards

Jun 10, 2025, 8:00 AM EDT - 9 months ago

Evolysse™ Recognized in 2025 Shape Skin Awards


Evolus Announces Departure of its Chief Financial Officer

May 27, 2025, 4:15 PM EDT - 9 months ago

Evolus Announces Departure of its Chief Financial Officer


Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:13 PM EDT - 10 months ago

Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript


Evolus Reports First Quarter 2025 Results

May 7, 2025, 4:05 PM EDT - 10 months ago

Evolus Reports First Quarter 2025 Results


Evolus to Report First Quarter Financial Results on May 7, 2025

Apr 23, 2025, 8:00 AM EDT - 10 months ago

Evolus to Report First Quarter Financial Results on May 7, 2025


Evolus Announces Commercial Launch of Evolysse™

Apr 16, 2025, 8:00 AM EDT - 11 months ago

Evolus Announces Commercial Launch of Evolysse™


Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 11:18 PM EST - 1 year ago

Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript


US FDA approves Evolus' anti-wrinkle gels

Feb 13, 2025, 1:45 PM EST - 1 year ago

US FDA approves Evolus' anti-wrinkle gels


Evolus Reports Third Quarter 2024 Results

Nov 6, 2024, 4:05 PM EST - 1 year ago

Evolus Reports Third Quarter 2024 Results


Evolus to Participate in Stifel 2024 Healthcare Conference

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Evolus to Participate in Stifel 2024 Healthcare Conference


Evolus, Inc. (EOLS) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 10:22 PM EDT - 1 year ago

Evolus, Inc. (EOLS) Q2 2024 Earnings Call Transcript


Evolus to Hold Investor Day on September 12, 2024

Jul 31, 2024, 8:00 AM EDT - 1 year ago

Evolus to Hold Investor Day on September 12, 2024


GrimTicker
GrimTicker Feb. 18 at 6:58 AM
$EOLS Evolus markets Jeuveau in aesthetics, gaining share in neuromodulator market but facing entrenched Botox competition and pricing pressure [citation:historical].
0 · Reply
kevinjewlurz
kevinjewlurz Feb. 13 at 3:27 PM
$EOLS @YugoSuperBeasT It seems like market still assumes cosmetic adoption curve when reimbursement language clearly anticipates therapeutic migration… right? specifically once CPT crosswalk guidance exits provisional status. We’re only 2 months away from complete protocol disengagement
0 · Reply
Bohrenn
Bohrenn Feb. 11 at 4:00 PM
$EOLS Sharedeals.de No Brainer Club with another rocket — strong buy below $10 USD
1 · Reply
KatherineBarnett501
KatherineBarnett501 Feb. 11 at 2:26 PM
$EOLS Evolus; aesthetics biotech (Jeuveau); gaining share in neuromodulator market; faces entrenched competition from AbbVie's Botox; pricing pressure is a margin headwind.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 6 at 6:25 PM
$EOLS Current Stock Price: $4.47 Contracts to trade: $5.0 EOLS Feb 20 2026 Call Entry: $0.23 Exit: $0.41 ROI: 80% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
chivo12
chivo12 Feb. 5 at 8:52 PM
$EOLS what an epic failure by executive management and the BOD. Trading at 1X revenue 7 years after commercial launch, and basically ignored by the investment community. Revenue guidance terrible. No path to positive GAAP earnings due to executive management hogs gorging themselves at the RSU and stock option trough ($20M impact annually!) and massive operating expenses that necessitate huge borrowing costs ($20M impact annually!). They talk about profitability in 2026 but they only mean non-GAAP. They won’t hit GAAP profitability until 2027…….9 years after their first product launch! Shameful! It is time for CEO to act like a grown up and slash operating expenses and give more realistic sales guidance ($350M - $360M in 2026) or else it is time to vote the BOD jokers out for not holding CEO accountable for this mess.
4 · Reply
Scamstock
Scamstock Feb. 5 at 8:02 PM
$EOLS did my second of up to 3 well spread out DCA first was 5.00 after today’s buy my average is now down to 4.76 one buy left I think this is due for a longer term reversal
0 · Reply
Bohrenn
Bohrenn Feb. 5 at 5:25 PM
$EOLS Mega NBC-Empfehlung zu $10,24; Stark Kaufen unter $10 - Sharedeals.de No Brainer Club Depot YTD bereits bei -22%;
1 · Reply
Longboardsoul
Longboardsoul Jan. 27 at 3:38 PM
$EOLS Why does David Moatazedi still have a job after this performance?
0 · Reply
lknite
lknite Jan. 26 at 7:32 PM
$EOLS ok, im in
0 · Reply
Mandi63
Mandi63 Jan. 24 at 8:14 PM
$AEON This drug is already sold though there European partner $EOLS ..
1 · Reply
S144
S144 Jan. 24 at 1:50 PM
$EOLS Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue https://uk.finance.yahoo.com/news/evolus-announces-preliminary-unaudited-fourth-133000108.html
0 · Reply
Scamstock
Scamstock Jan. 22 at 3:38 PM
$EOLS got a starter today first of up to 3 well spread out buys over the next hours to next 2 weeks I like the decreasing daily volume makes me feel we are at approximate bottom shorts and sellers getting bored
0 · Reply
Mandi63
Mandi63 Jan. 22 at 2:39 PM
$AEON$AEON $2.00-5.00 let it run.. $OPEN $EOLS
1 · Reply
RocketThief
RocketThief Jan. 21 at 6:16 PM
$EOLS adding a bit and will continue to scale if it goes to lower 4s. If they can hit profitability in ‘26 as they’ve recently claimed this could be a multibagger
1 · Reply
mlanthoo
mlanthoo Jan. 16 at 11:49 PM
$EOLS finally found some buying today .
0 · Reply
StockHunter75
StockHunter75 Jan. 16 at 7:41 PM
$EOLS Calling bottom.
0 · Reply
RocketThief
RocketThief Jan. 15 at 7:07 PM
$EOLS high $4S starter on turnaround potential
0 · Reply
Longboardsoul
Longboardsoul Jan. 15 at 3:55 PM
$EOLS Trading just above 1x sales is baffling especially when they have reiterated positive cash flows for this year onwards. In the face of this pain, I believe this is a big time buying opportunity. Time will tell.
0 · Reply
StockHunter75
StockHunter75 Jan. 15 at 3:11 PM
$EOLS Load up the dip, shorts will cover or get burned.
0 · Reply
Luckyluck39
Luckyluck39 Jan. 15 at 12:45 PM
$EOLS I think this isn't the end of the decline. Maybe it will stop at 3-4 USD.
0 · Reply
mlanthoo
mlanthoo Jan. 15 at 12:02 AM
$EOLS lowered guidance really has hurt . Will another company show interest in the acquisition of the portfolio? Otherwise their pay only could suffer in a slowing economy.
0 · Reply